BXL0124
BXL0124 is an orally effective CD44 inhibitor and Notch signaling pathway inhibitor. BXL0124 has a vitamin D receptor-dependent mechanism and can downregulate the expression of CD44, Notch1/2/3, HES1, OCT4, LAMA5, JAG1, JAG2, NF-κB and DLL1. BXL0124 inhibits c-Myc expression and the levels of phosphorylated ERK, AKT, ErbB2, reduces the level of activated Notch1 receptor and its nuclear localization, decreases the mRNA and protein levels of Jagged-1 and Jagged-2, and inhibits the STAT3 signaling pathway by reducing the formation of the CD44-STAT3-JAK2 complex, while also inhibiting the transcriptional activity of the CD44 promoter in a p53-dependent manner. BXL0124 can induce myoepithelial differentiation and inhibit the self-renewal of cancer stem cell-like cells, cancer cell proliferation, invasion, and growth. BXL0124 can be used in research related to triple-negative breast cancer, basal-like breast cancer, ErbB2-overexpressing mammary tumorigenesis, and breast cancer.
For research use only. We do not sell to patients.
- CAS No.: 685141-23-5
- Formula: C32H44F6O4
- Molecular Weight:606.68
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
[1]|
STAT3 |
In Vitro
BXL0124 (1-100 nM; 5 days) potently reduces mammosphere formation efficiency and self-renewal capacity in SUM159 triple-negative breast cancer cells[1].
BXL0124 (10 nM; 5 days) downregulates the expression of pluripotency and cancer stem cell markers in SUM159 triple-negative breast cancer mammospheres[1].
BXL0124 (10 nM; 5 days) inhibits the expression of Notch signaling pathway molecules in SUM159 triple-negative breast cancer mammospheres[1].
BXL0124 (10 nM; 5 days) can modulate the expression of mammary epithelial differentiation markers in SUM159 triple-negative breast cancer mammospheres[1].
BXL0124 (10 nM; 72 h) inhibits the proliferation of CD44+/CD24−, CD44+/CD24low, and CD44+/CD24high MCF10DCIS basal-like breast cancer cells[2].
BXL0124 (10 nM; 24 h) reduces the protein levels of c-Notch1, Jagged-2, and c-Myc in CD44+/CD24−, CD44+/CD24low, and CD44+/CD24high MCF10DCIS basal-like breast cancer cells[2].
BXL0124 (0.1-10 nM; 24 h) inhibits the Notch signaling pathway in MCF10DCIS basal-like breast cancer cells in a dose-dependent manner in vitro, reducing the levels of c-Notch1, Notch3, Jagged-1, Jagged-2, DLL1, and c-Myc proteins[2].
BXL0124 (10 nM; 1-24 h) decreased the protein levels of c-Notch1, Jagged-1, and Jagged-2 in MCF10DCIS basal-like breast cancer cells in a time-dependent manner[2].
BXL0124 (10 nM; 24 h) reduces nuclear levels of activated c-Notch1 and increases nuclear VDR levels in MCF10DCIS basal-like breast cancer cells[2].
BXL0124 (10 nM; 24 h) inhibits the Notch1 signaling pathway in MCF10DCIS basal-like breast cancer cells in a VDR-dependent manner[2].
BXL0124 (10 nM; 24 h) inhibits Notch1 signaling in MCF10DCIS basal-like breast cancer cells in a HES1-dependent manner[2].
BXL0124 (10 nM; 1-24 h) increases HES1 mRNA levels in MCF10DCIS basal-like breast cancer cells, while decreasing the mRNA levels of Jagged-1, Jagged-2, DLL1, and c-Myc, but the mRNA levels of Notch receptors remain unchanged[2].
BXL0124 (10 nM; 30 min-24 h) rapidly and persistently upregulates HES1 mRNA and protein levels in MCF10DCIS basal-like breast cancer cells[2].
BXL0124 (administered continuously for 3 days) potently inhibits the proliferation of ErbB2-overexpressing E18-9A-42 breast tumor cells, with an IC50 of 0.04 nM[3].
BXL0124 (24 h incubation) reduces plasma membrane-localized phosphorylated AKT levels in E18-9A-42 ErbB2-overexpressing breast tumor cells[3].
BXL0124 (0.01-100 nM; 72 h) potently inhibits the proliferation of MCF10DCIS basal-like human breast cancer cells[4].
BXL0124 (0.01-100 nM; 24-72 h) inhibits the metabolic activity of MCF10DCIS basal-like human breast cancer cells[4].
BXL0124 (1-10 nM; 48 h) inhibits the invasion of MCF10DCIS basal-like human breast cancer cells in a BME-coated invasion assay[4].
BXL0124 (1-10 nM; 10 days) inhibits the invasive growth of MCF10DCIS basal-like human breast cancer cells in 3D Matrigel culture assays[4].
BXL0124 (10 nM; 24-48 h) inhibits the mRNA expression of CD44, MMP-2, MMP-9, and uPA in MCF10DCIS basal-like human breast cancer cells[4].
BXL0124 (0.1-10 nM; 24 h) dose-dependently inhibited the protein levels of CD44 and pSTAT3 in MCF10DCIS basal-like human breast cancer cells, without altering the protein levels of total STAT3, Akt, Erk, or NFκB[4].
BXL0124 (10 nM; 24 h)-mediated downregulation of CD44 and pSTAT3 protein levels in MCF10DCIS basal-like human breast cancer cells is a VDR-dependent process[4].
BXL0124 (10 nM; 24 h) reduces nuclear localization of phosphorylated STAT3 in MCF10DCIS basal-like human breast cancer cells[4].
BXL0124 (0.1-10 nM; 24 h) inhibits STAT3 DNA-binding activity in MCF10DCIS basal-like human breast cancer cells in a dose-dependent manner[4].
BXL0124 (10 nM; 24 h) reduces the formation of CD44-STAT3-JAK2 protein complexes in MCF10DCIS basal-like human breast cancer cells and decreases the levels of phosphorylated STAT3 in these complexes[4].
BXL0124 (10 nM; 24 h) upregulates VDR protein levels and inhibits CD44 and pSTAT3 protein levels in MCF10CA1a and MDA-MB-468 basal-like human breast cancer cells[4].
BXL0124 (0.01-10 nM; 1-72 h) potently inhibits CD44 expression through a VDR- and p53-dependent mechanism, reduces the CD44+/high/CD24−/low breast cancer stem cell subpopulation, and induces osteopontin mRNA expression in MCF10DCIS.com human breast cancer cells in vitro[5].
BXL0124 (incubation for 24 h) downregulates the phosphorylation levels of ErbB2, ERK, and AKT in E18-9A-42 ErbB2-overexpressing breast tumor cells and decreases cyclin D1 expression, without affecting the total protein levels of ErbB2, ERK, or AKT[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:CD44+/CD24−, CD44+/CD24low, and CD44+/CD24high subpopulations of MCF10DCIS basal-like breast cancer cells
-
Concentration:10 nM
-
Incubation Time:72 h
-
Result:Reduced cell proliferation rates in all three sorted subpopulations to ~25% of control in CD44+/CD24− cells, ~28% of control in CD44+/CD24low cells, and ~20% of control in CD44+/CD24high cells.
-
Cell Line:CD44+/CD24−, CD44+/CD24low, and CD44+/CD24high subpopulations of MCF10DCIS basal-like breast cancer cells
-
Concentration:10 nM
-
Incubation Time:24 h
-
Result:Decreased protein levels of activated Notch1 (c-Notch1), Jagged-2, and c-Myc in all three sorted subpopulations.
-
Cell Line:MCF10DCIS basal-like breast cancer cells
-
Concentration:0.1-10 nM
-
Incubation Time:24 h
-
Result:Decreased protein levels of c-Notch1, total Notch3, Jagged-1, Jagged-2, DLL1, and c-Myc in a dose-dependent manner, with the greatest effects on c-Notch1 and Jagged-2.
Left total Notch1 and total Notch2 protein levels unaffected.
Showed stronger inhibitory activity than 1α,25(OH)2D3 at equivalent concentrations.
-
Cell Line:MCF10DCIS basal-like breast cancer cells
-
Concentration:10 nM
-
Incubation Time:1-24 h
-
Result:Markedly reduced c-Notch1 protein levels at 12 h and 24 h, while total Notch1 levels remained unchanged.
Reduced Jagged-1 protein levels at 4 h, 12 h, and 24 h.
Reduced Jagged-2 levels at 12 h and 24 h.
-
Cell Line:MCF10DCIS basal-like breast cancer cells
-
Concentration:10 nM
-
Incubation Time:24 h
-
Result:Had its ability to decrease c-Notch1 and Jagged-2 protein levels reduced by VDR knockdown, confirming inhibition of Notch1 activation is VDR-dependent.\nHad its ability to decrease c-Notch1 and Jagged-2 protein levels reduced by partial HES1 knockdown, indicating inhibition of Notch1 signaling is HES1-dependent.
Still increased HES1 protein levels despite knockdown.
Left VDR induction unaffected by HES1 knockdown.
-
Cell Line:MCF10DCIS basal-like breast cancer cells
-
Concentration:10 nM
-
Incubation Time:1-24 h
-
Result:Did not affect mRNA levels of Notch1, Notch2, or Notch3.
Significantly decreased mRNA levels of Jagged-1, Jagged-2, and DLL1 at 8 h, 16 h, and 24 h.
Significantly decreased c-Myc mRNA levels at 16 h and 24 h.
Rapidly and significantly increased HES1 mRNA levels at all time points tested, including as early as 1 h.
-
Cell Line:MCF10DCIS basal-like human breast cancer cells
-
Concentration:0.01-100 nM
-
Incubation Time:72 h
-
Result:Potently inhibited MCF10DCIS cell proliferation, with greater potency than 1α,25(OH)2D3.
Caused a marked reduction in [3H]thymidine incorporation compared to untreated cells at 1, 10, and 100 nM.
-
Cell Line:MCF10DCIS basal-like human breast cancer cells
-
Concentration:0.01-100 nM
-
Incubation Time:24-72 h
-
Result:Inhibited MCF10DCIS cell metabolic activity in a time-dependent manner, with greater potency than 1α,25(OH)2D3.
Caused a significant reduction in absorbance at 560 nm compared to untreated cells at 10 and 100 nM at 72 h.
-
Cell Line:MCF10DCIS basal-like human breast cancer cells
-
Concentration:1-10 nM
-
Incubation Time:48 h
-
Result:Significantly reduced the number of MCF10DCIS cells that penetrated the BME layer, with greater effectiveness than 1α,25(OH)2D3.
Caused a marked decrease in invaded cell counts compared to untreated cells at 10 nM.
-
Cell Line:MCF10DCIS basal-like human breast cancer cells
-
Concentration:1-10 nM
-
Incubation Time:10 days (medium replenished every 2 days)
-
Result:Abolished the invasive outgrowth of MCF10DCIS cells observed in untreated control cultures.
Resulted in only non-invasive cell clusters, unlike control cultures which exhibited invasive protrusions.
-
Cell Line:MCF10DCIS basal-like human breast cancer cells
-
Concentration:10 nM
-
Incubation Time:24-48 h
-
Result:Significantly decreased mRNA expression levels of CD44, MMP-2, MMP-9, and uPA at both 24 h and 48 h.
Did not significantly change mRNA expression of MMP-14.
-
Cell Line:MCF10DCIS basal-like human breast cancer cells
-
Concentration:0.1-10 nM (24 h dose-dependent study); 10 nM (6-24 h time-dependent study)
-
Incubation Time:24 h (dose-dependent study); 6-24 h (time-dependent study)
-
Result:Decreased protein levels of CD44 variant isoforms (CD44v, 100-250 kDa), CD44 standard isoform (CD44s, 85 kDa), and phosphorylated STAT3 (pSTAT3) in a dose-dependent manner at 24 h.
Left total STAT3, phosphorylated Akt (pAkt), total Akt, phosphorylated Erk (pErk), total Erk, phosphorylated NFκB (pNFκB), and total NFκB levels unchanged.
Decreased CD44s, CD44v, and pSTAT3 levels at 12 h and 24 h in a time-dependent study, while total STAT3 levels remained unchanged.
-
Cell Line:MCF10DCIS basal-like human breast cancer cells
-
Concentration:10 nM
-
Incubation Time:24 h (after 72 h siRNA transfection)
-
Result:Abolished the repression of CD44v, CD44s, and pSTAT3 protein levels in cells transfected with VDR siRNA, compared to cells transfected with non-targeting siRNA.
-
Cell Line:MCF10DCIS basal-like human breast cancer cells
-
Concentration:10 nM
-
Incubation Time:24 h
-
Result:Reduced strong nuclear staining of pSTAT3 observed in untreated control cells, indicating decreased nuclear localization of activated STAT3.
-
Cell Line:MCF10DCIS basal-like human breast cancer cells
-
Concentration:10 nM
-
Incubation Time:24 h
-
Result:Decreased the amounts of CD44v, CD44s, and pSTAT3 in complexes immunoprecipitated with anti-STAT3 antibody, while total STAT3 levels remained unchanged.
Decreased the amount of JAK2 associated with STAT3, while Src association with STAT3 was unchanged.
Decreased the amounts of CD44v, CD44s, and pSTAT3 in complexes immunoprecipitated with anti-JAK2 antibody, while JAK2 levels remained unchanged.
-
Cell Line:MCF10CA1a and MDA-MB-468 basal-like human breast cancer cells
-
Concentration:10 nM
-
Incubation Time:24 h
-
Result:Increased vitamin D receptor (VDR) protein levels in both cell lines.
Decreased protein levels of CD44v, CD44s, and pSTAT3 in both cell lines.
Left total STAT3 protein levels unchanged in both cell lines.
-
Cell Line:MCF10DCIS.com human breast cancer cells
-
Concentration:0.01-10 nM (Western blot, 24 h); 10 nM (flow cytometry, fluorescence microscopy, VDR siRNA assay, time-course mRNA analysis, 24 h); 0.01-10 nM (dose-dependent mRNA analysis, 4 h); 0.1-10 nM (CD44 promoter assay, 24 h); 1 μM VDR siRNA (72 h, followed by 10 nM BXL0124 for 24 h)
-
Incubation Time:24 h (Western blot, flow cytometry, fluorescence microscopy, VDR siRNA assay, CD44 promoter assay); 1, 4, 12, 24 h (time-course mRNA analysis); 4 h (dose-dependent mRNA analysis); 72 h (VDR siRNA incubation, followed by 24 h BXL0124 treatment)
-
Result:Down-regulated CD44 standard isoform (CD44s, 85 kDa) and CD44 variant isoforms (CD44v, 100-250 kDa) protein expression in a dose-dependent manner, with greater potency than 1α,25-dihydroxyvitamin D3.
Decreased the fraction of CD44+/high/CD24-/low cells from 17.0% to 8.5%, and increased the fraction of CD44+/high/CD24+/high cells from 83.0% to 91.5%.
Reduced CD44 protein expression on the plasma membrane, with no change in subcellular localization.
Had its CD44 protein repression effect blocked by VDR siRNA knockdown, confirming VDR dependence.
Down-regulated CD44 mRNA expression with maximum inhibition at 4 h, and in a dose-dependent manner at 4 h, with greater potency than 1α,25-dihydroxyvitamin D3.
Induced osteopontin mRNA expression starting at 4 h, with stronger induction than 1α,25-dihydroxyvitamin D3 at 24 h, and in a dose-dependent manner at 4 h.
Repressed transactivation of the full-length CD44 promoter in a dose-dependent manner, with greater potency than 1α,25-dihydroxyvitamin D3; this repression was abolished by p53-binding site mutation in the CD44 promoter, confirming p53 dependence.
In Vivo
BXL0124 (0.3 μg/kg BW; i.p.; three times weekly; 54 weeks) inhibits ErbB2-overexpressing mammary tumor growth by 57% (tumor volume) and 54% (tumor weight) in MMTV-ErbB2/neu transgenic mice via down-regulation of ErbB2/AKT/ERK signaling and cyclin D1 expression, without inducing hypercalcemic toxicity[3].
BXL0124 (0.1 μg/kg; p.o.; 6 days a week; 5 weeks) suppresses MCF10DCIS.com xenograft breast tumor growth by 52% (tumor weight reduction) and represses CD44 and PCNA expression in nu/nu mice without hypercalcemic toxicity[5].
BXL0124 inhibits growth of MCF10DCIS xenograft tumors in immunodeficient nu/nu mice[4].
BXL0124 (0.03-0.1 μg/kg; i.p., p.o.; 6 days a week; 5 weeks) suppresses MCF10DCIS.com xenograft breast tumor growth by 66% (tumor weight reduction) via intraperitoneal administration at 0.1 μg/kg, while oral administration at 0.03 μg/kg and 0.1 μg/kg reduces tumor growth by 37% and 52% (tumor weight reduction), respectively, in SCID mice without hypercalcemic toxicity[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:MMTV-ErbB2/neu transgenic (6-7 weeks old at study start)[3]
-
Dosage:0.3 μg/kg BW
-
Administration:i.p.; three times weekly; 54 weeks
-
Result:Reduced mean mammary tumor volume to 0.54 cm3, corresponding to 57% growth inhibition compared to controls.
Reduced mean tumor weight to 0.36 gram, corresponding to 54% inhibition compared to controls.
Reduced mean tumor multiplicity by 54% compared to controls.
Did not affect mouse body weight or induce hypercalcemic toxicity.
Down-regulated the phosphorylation of ErbB2, ERK, and AKT without altering total protein levels of these molecules in mammary tumors.
Reduced expression of the cell proliferation marker cyclin D1 in mammary tumors.
-
Animal Model:nu/nu[5]
-
Dosage:0.1 μg/kg
-
Administration:p.o.; 6 days a week; 5 weeks
-
Result:Suppressed tumor size by 47% and tumor weight by 52%.
Markedly down-regulated protein expression of CD44 standard isoform (CD44s, 85 kDa), CD44 variant isoforms (CD44v, 100-250 kDa), CD44v3, and CD44v6 in xenograft tumors.
Reduced the proportion of cells with strong CD44 membrane staining (3+) from 48% to 15%, and reduced PCNA-positive cells from 82% to 62%.
No significant changes in body weight or serum calcium levels were observed.
-
Animal Model:Severe combined immunodeficiency (SCID)[5]
-
Dosage:0.1 μg/kg (i.p.); 0.03 μg/kg (p.o.); 0.1 μg/kg (p.o.)
-
Administration:i.p.; 6 days a week; 5 weeks; p.o.; 6 days a week; 5 weeks
-
Result:Reduced average tumor volume by 75% and tumor weight by 66% at 0.1 μg/kg i.p..
Reduced tumor volume by 36% and tumor weight by 37% at 0.03 μg/kg p.o..
Reduced tumor volume by 49% and tumor weight by 52% at 0.1 μg/kg p.o..
No significant changes in body weight or serum calcium levels were observed with any dose or route tested.
Chemical Information
-
CAS No. 685141-23-5
-
Molecular Weight 606.68
-
Formula C32H44F6O4
-
SMILES
C[C@@]12[C@](CC[C@]2([H])[C@H](CCCC(C)(O)C)CC#CC(C(F)(F)F)(O)C(F)(F)F)([H])/C(CCC1)=C/C=C3C([C@H](C[C@@H](C\3)O)O)=C
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
-
Somatic Cell Culture
A method of simulating the in vivo environment in vitro to maintain the cell growth, differentation and main functions.
-
CFSE Dye Dilution Proliferation Assay
The CFSE (carboxyfluorescein diacetate succinimidyl ester) dye dilution proliferation assay is based on the covalent labeling of intracellular proteins by a cell-permeant fluorescent dye that becomes fluorescent upon intracellular ester cleavage and then is stably retained within cells. As labeled cells divide, the dye is partitioned equally between daughter cells, resulting in a stepwise halving of fluorescence intensity that can be quantified by flow cytometry to determine the number of cell divisions undergone by each cell population. This fluorescence dilution approach enables quantitative tracking of lymphocyte proliferation at the single-cell level over multiple rounds of division. CFSE-based proliferation analysis has been widely applied to measure antigen-driven lymphocyte expansion in vitro, where discrete fluorescence peaks correspond to successive cell divisions and allow reconstruction of proliferative history within heterogeneous populations.
-
Dye-dilution cell tracking and proliferation staining
Dye-dilution cell tracking assays quantify cell proliferation by covalently labeling intracellular proteins with a stable fluorescent dye that is equally partitioned between daughter cells during mitosis, resulting in stepwise halving of fluorescence intensity with each cell division as measured by flow cytometry histograms. Carboxyfluorescein diacetate succinimidyl ester (CFSE) is a prototypical dye that diffuses into cells, is enzymatically converted into a fluorescent compound, and then covalently binds intracellular amine groups, producing long-lived fluorescence suitable for tracking multiple rounds of division in vitro and in vivo. Successive generations of dividing cells form discrete peaks of decreasing fluorescence intensity, enabling estimation of proliferation history, precursor frequency, and division index within heterogeneous populations. Alternative dyes such as CellTrace Violet (CTV) and far-red membrane dyes (e. g. , PKH26) follow the same dilution principle but differ
-
CCK-8/WST-8 Cell Proliferation Assay
The CCK-8/WST-8 assay is based on the reduction of the water-soluble tetrazolium salt WST-8 to a water-soluble formazan product by cellular dehydrogenases in metabolically active cells, where the generated formazan amount is proportional to the number of living cells and is quantified by measuring absorbance in the visible range, providing a colorimetric readout for cell viability and proliferation assessment. This class of tetrazolium-based assays improves upon earlier MTT-based systems by producing a water-soluble formazan, eliminating the need for organic solubilization steps and enabling direct spectrophotometric measurement in culture medium.
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Cell Counting-Based Growth Curve Assay
Cell counting-based growth curve assays quantify cell proliferation by directly measuring changes in viable cell number over time using manual or automated counting methods such as hemocytometer-based counting or instrument-assisted cell enumeration, enabling construction of growth curves that reflect population expansion dynamics in response to culture conditions. A widely used approach is trypan blue exclusion with hemocytometer counting, where membrane-compromised (non-viable) cells take up the dye, allowing discrimination between viable and non-viable cells while simultaneously enabling total cell number quantification. Repeated sampling across time points allows estimation of proliferation rate, growth phases, and comparative growth kinetics between experimental conditions.
-
Colony Formation (Clonogenic) Assay
The clonogenic (colony formation) assay measures the ability of a single cell to retain reproductive viability and form a macroscopic colony, typically defined as a cluster derived from one progenitor cell after a defined growth period. This assay is widely used to evaluate cell survival after exposure to ionizing radiation or cytotoxic treatments and is considered a standard method in radiation biology for generating dose-response relationships of reproductive cell death. Colony formation reflects long-term proliferative capacity rather than short-term metabolic activity, and survival is quantified by comparing treated versus untreated conditions based on colony number and derived survival fractions.
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
-
Dual Luciferin reporter gene assay
Luciferin reporter gene assay is a reporting system to detect the activity of Firefly Luciferase using luciferin as a substrate, which is often used in the research of miRNA target gene verification and promoter transcriptive activity regulation. Dual luciferase usually refers to Firefly luciferase and Renilla luciferase.
-
EdU Incorporation Assay (Click Chemistry-Based DNA Synthesis Measurement)
The EdU incorporation assay measures DNA synthesis by adding the thymidine analog 5-ethynyl-2′-deoxyuridine to cells or tissues, where it is incorporated into newly synthesized DNA during S phase. Incorporated EdU is detected by copper-catalyzed azide-alkyne cycloaddition, in which a fluorescent azide covalently reacts with the ethynyl group on EdU, allowing S-phase cells to be detected by fluorescence microscopy, flow cytometry, or high-content imaging. EdU detection does not require DNA denaturation or anti-BrdU antibody access, which preserves sample structure and improves compatibility with immunostaining and multiparameter cytometry compared with BrdU-based detection. EdU can be cytotoxic in a cell-type- and exposure-dependent manner, so pulse duration, concentration, and continuous-labeling designs should be validated for each cell type.
-
Ki-67 Immunostaining Proliferation Assay
Ki-67 immunostaining measures the growth fraction of a cell population by detecting Ki-67, a nuclear antigen present in proliferating cells and absent in quiescent G0 cells. The readout is the percentage of Ki-67-positive nuclei among total counted cells, commonly called the Ki-67 labeling index or proliferation index.
-
PCNA Immunodetection Proliferation Assay
PCNA immunodetection measures proliferative activity by detecting proliferating cell nuclear antigen, a nuclear protein associated with DNA polymerase δ function and DNA replication. The assay readout is the proportion of PCNA-positive nuclei among total counted cells, but PCNA labeling is not identical to BrdU labeling because PCNA can mark late G1/early S-associated replication competence and may persist beyond active DNA synthesis depending on fixation and extraction conditions.
-
Protocol for Cell Counting and Cell Density Analysis
Cell counting and cell-density analysis estimate the number of cells in a known volume or field area. Manual hemocytometer counting uses a chamber of defined geometry to convert counted cells into cells/mL, while automated counters and image-analysis workflows detect cell objects from optical, brightfield, fluorescence, impedance, or digital-image features. Trypan blue viability counting is based on dye exclusion: viable cells with intact membranes exclude dye, while non-viable cells with compromised membranes stain blue. The readout is total cell density, viable-cell density, dead-cell density, and percent viability. Cell density can also be estimated from microscopy images by counting objects per image area, from flow cytometry using calibrated volume or reference particles, or from in situ microscopy in bioreactors after calibration against reference methods such as hemocytometer or flow cytometry.
-
Notch Pathway Solutions
The Notch pathway is a contact-dependent signaling pathway that controls cell-fate decisions, differentiation, proliferation, and tissue patterning through interactions between membrane-bound Notch receptors and membrane-bound ligands on neighboring cells. Canonical Notch signaling is activated when ligand engagement triggers proteolytic release of the Notch intracellular domain, which enters the nucleus and regulates transcription together with DNA-binding transcriptional complexes. In the canonical mechanism, ligand-dependent Notch activation leads to release of the intracellular Notch domain, and presenilin-dependent γ-secretase activity is required for production of the active intracellular signaling fragment. The released intracellular domain functions as a nuclear signal that converts Notch receptor activation at the membrane into transcriptional regulation of target programs such as HES/HEY-family genes and other context-dependent downstream targets. The literature links Notch p
-
Cell invasion
Cell invasion is the ability of cells to migrate from one area to another via the extracellular matrix. Cell invasion is the response of normal and cancer cells to chemical and mechanical stimuli. Before migrating to a new region, the extracellular matrix is degraded by proteases within the cell. Cell invasion often occurs during wound repair, vascularization and inflammation, abnormal tissue invasion, and tumor cell metastasis.
-
MTT Cell Proliferation Assay
The MTT assay is a colorimetric endpoint assay for estimating viable cell number, cell growth, cytotoxicity, or cell activation in cultured mammalian cells. Living cells reduce the yellow tetrazolium salt MTT into purple/blue formazan, while dead cells do not generate the same signal; the resulting color can be quantified with a multiwell spectrophotometer. MTT reduction is commonly interpreted as a readout of metabolic activity that often correlates with viable cell number, but it should not be treated as a direct cell-counting method unless the assay is optimized for the cell type and experimental condition. Studies show that MTT reduction can involve mitochondrial and non-mitochondrial reducing systems, and formazan may accumulate in intracellular lipid droplets rather than simply marking mitochondria.
-
hPSC maintenance and expansion
This protocol maintains and expands human pluripotent stem cells under feeder-free, chemically defined conditions using E8 medium and vitronectin-coated culture surfaces; the readout is sustained adherent colony growth with undifferentiated morphology and retained pluripotency-marker expression during serial passaging. E8-based hPSC culture relies on defined soluble factors and matrix-dependent adhesion rather than feeder cells; vitronectin supports hPSC attachment through integrin-mediated interactions, and EDTA passaging dissociates colonies as small aggregates without enzymatic digestion, centrifugation, or routine ROCK-inhibitor treatment.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)